Johnson announced an agreement on Tuesday to pay $8.9 billion to tens of thousands of people who say the company’s talcum powder products caused cancer
However, Johnson & Johnson
— The drug and consumer products maker said first quarter sales rose 5.6% to $24.75 billion, above the $23.67 billion consensus estimate of analysts polled by Refinitiv. Adjusted earnings came in at $2.68 per share ex-items, above the consensus estimate of $2.50. The CEO noted “strong performance” across all three business segments with the company raising 2023 guidance midpoints. Shares of the Dow Industrials constituent gained more than 1% premarket.
Marshsyl com
Kindly click here to join our Telegram channel
Comments